Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ole Dyg Pedersen

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Expert Opinion on Emerging Drugs|July 2, 2005
The immediate future for the medical treatment of atrial fibrillationOle Dyg Pedersen, Bente Brendorp, Lars Køber, et al.
Expert Opinion on Emerging Drugs|June 7, 2005
New antiarrhythmic agents for atrial fibrillation and atrial flutterRedi Pecini, Hanne Elming, Ole Dyg Pedersen, et al.
Congestive Heart Failure (Greenwich, Conn.)|December 23, 2003
Prevalence, prognostic significance, and treatment of atrial fibrillation in congestive heart failure with particular reference to the DIAMOND-CHF studyOle Dyg Pedersen, Bente Brendorp, Lars Køber, et al.
International Journal of Cardiology|April 12, 2005
Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following acute myocardial infarctionOle Dyg Pedersen, Henning Bagger, Lars Køber, et al.
Expert Opinion on Pharmacotherapy|June 5, 2003
Dofetilide: a new drug to control cardiac arrhythmiaHanne Elming, Bente Brendorp, Ole Dyg Pedersen, et al.
Expert Review of Cardiovascular Therapy|March 20, 2004
Can antiarrhythmic drugs save lives in patients with congestive heart failure?Bente Brendorp, Ole Dyg Pedersen, Hanne Elming, et al.
Expert Opinion on Drug Safety|October 27, 2004
A benefit-risk assessment of class III antiarrhythmic agentsHanne Elming, Bente Brendorp, Steen Pehrson, et al.
Cardiac Electrophysiology Review|January 24, 2004
Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) studyOle Dyg Pedersen, Bente Brendorp, Hanne Elming, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|November 6, 2013
Diagnostic value of exercise-induced changes in circulating high sensitive troponin T in stable chest pain patientsMette Rauhe Mouridsen, Olav Wendelboe Nielsen, Ole Dyg Pedersen, et al.
European Heart Journal|November 4, 2005
Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarctionOle Dyg Pedersen, Steen Z Abildstrøm, Michael M Ottesen, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Expert Opinion on Emerging Drugs|July 2, 2005
The immediate future for the medical treatment of atrial fibrillationOle Dyg Pedersen, Bente Brendorp, Lars Køber, et al.
Expert Opinion on Emerging Drugs|June 7, 2005
New antiarrhythmic agents for atrial fibrillation and atrial flutterRedi Pecini, Hanne Elming, Ole Dyg Pedersen, et al.
Congestive Heart Failure (Greenwich, Conn.)|December 23, 2003
Prevalence, prognostic significance, and treatment of atrial fibrillation in congestive heart failure with particular reference to the DIAMOND-CHF studyOle Dyg Pedersen, Bente Brendorp, Lars Køber, et al.
International Journal of Cardiology|April 12, 2005
Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following acute myocardial infarctionOle Dyg Pedersen, Henning Bagger, Lars Køber, et al.
Expert Opinion on Pharmacotherapy|June 5, 2003
Dofetilide: a new drug to control cardiac arrhythmiaHanne Elming, Bente Brendorp, Ole Dyg Pedersen, et al.
Expert Review of Cardiovascular Therapy|March 20, 2004
Can antiarrhythmic drugs save lives in patients with congestive heart failure?Bente Brendorp, Ole Dyg Pedersen, Hanne Elming, et al.
Expert Opinion on Drug Safety|October 27, 2004
A benefit-risk assessment of class III antiarrhythmic agentsHanne Elming, Bente Brendorp, Steen Pehrson, et al.
Cardiac Electrophysiology Review|January 24, 2004
Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) studyOle Dyg Pedersen, Bente Brendorp, Hanne Elming, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|November 6, 2013
Diagnostic value of exercise-induced changes in circulating high sensitive troponin T in stable chest pain patientsMette Rauhe Mouridsen, Olav Wendelboe Nielsen, Ole Dyg Pedersen, et al.
European Heart Journal|November 4, 2005
Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarctionOle Dyg Pedersen, Steen Z Abildstrøm, Michael M Ottesen, et al.
Pageof 3